Online ISSN: 2515-8260

Keywords : Thymoquinone


In-Silico Docking studies of thymoquinone as potential anti-cancer drug target on Lung Cancer Cells

B. DURGA; A. JULIUS

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 3, Pages 1706-1716

Understanding the inhibitory mechanism of thymoquinone targeting proteins involved in lung cancer. Thymoquinone were reported as possible anti-cancer drug targeting the gene containing protein like GTPase KRas in the cancer inducing pathways and we have used molecular docking in order to understand the underlying mechanism. The target proteins were preferred from various studies in cancer inducing pathways were docked by thymoquinone and also with its analogue poloxime. Protein-ligand complexes were selected based on the binding energy ranked from lowest to highest according to thymoquinone. Our results identified that thymoquinone inhibiting GTPase KRas, Sir-2, ALK5 and β-Catenin,. The docking study also establishes the multifaceted role of thymoquinone as a chemo preventive anti-cancer agent against lung cancer. These in-silico study report would be the substantial platform for the drugs to be focused in future for in-vitro and in-vivo studies for exploring its multitude function for providing a functional strategy for using as a therapeutic agent against cancer.

Effect of locally delivered 0.2% Thymoquinone gel in subjects with Grade C Periodontitis: Clinical, Immunological and Microbiological Assessment

Walid Elamrousy

European Journal of Molecular & Clinical Medicine, 2018, Volume 5, Issue 1, Pages 89-101
DOI: 10.31838/ejmcm.05.01.11

To evaluate the clinical, immunological and microbiological efficacy of local application of Thymoquinone (TQ) gel in subjects with grade C periodontitis. Materials and Methods: Twenty-six individuals of both sexes aged between24 and 37 years, diagnosed as grade C periodontitis with pocket depth ≥5 mm were selected for this study. The patients received a complete prophylaxis including scaling and root planning (SRP) followed by local intrapocket administration of placebo gel in the control group and 0.2% TQ gel in the study group sites. Probing pocket depth (PPD), relative attachment level (RAL), matrix metallo-proteniease-8 (MMP8) concentration in
gingival crevicular fluid (GCF) and Aggregatibacter actinomycetecomitans (A.a) count in subgingival plaque were measured and recorded at baseline and 8 weeks postoperatively. Results: At 8 weeks evaluation period, TQ group showed a significant reduction in PPD, RAL, MMP-8 levels in GCF and A.a count in subgingival plaque samples when compared to the placebo group. Conclusion: The results showed more favorable clinical, immunological and microbiological outcomes with topically administered 0.2 % TQ gel when used as an adjunct to nonsurgical periodontal therapy in subjects with grade C periodontitis.